Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in CKD patients with high fracture risk
NCT05692297Recruiting
- Sponsor
- Capital Medical University
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of denosumab in chronic kidney disease-mineral and bone disorder (CKD-MBD) (2 arms), sponsored by Capital Medical University. Primary endpoint: Rate of bone mineral density (BMD) decline at the lumbar spine at 24 months. Started Jan 2023; status: recruiting.
02
Drugs
denosumab
03
Conditions
chronic kidney disease-mineral and bone disorder (CKD-MBD)
Beyond the preview
Go deeper on NCT05692297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05692297.